BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Auricula Biosciences Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Auricula Biosciences Inc.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07148128-2804@assetmemo.bio
DTSTAMP:20261121T005929Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:WEF-001: Phase 1/2 readout est. (NCT07148128)
DESCRIPTION:WEF-001\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  1/2a Study to Assess the Safety\, Tolerability\, Pharmacokinetics\, and P
 reliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Soli
 d Tumours.\nEstimated primary completion: January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/wef-001#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07148128
URL:https://assetmemo.bio/drug/wef-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
